Dewpoint Therapeutics
Dewpoint Therapeutics is a leading biotechnology company focused on translating condensate biology into novel therapies. By understanding that the dysregulation of biomolecular condensates is the root cause of complex diseases, Dewpoint is developing a new generation of medicines. They integrate AI with state-of-the-art experimental technologies to create a fully integrated discovery platform. The company has a diverse pipeline and has formed strategic partnerships with major global pharmaceutical companies like Bayer, Novo Nordisk, Evotec, Mitsubishi Tanabe Pharma Corporation, and ConcertAI. Dewpoint Therapeutics has raised significant funding, with over $287M in Series A, B, and C rounds. They have also announced development candidates such as DPTX3496 for cancers and are exploring treatments for ALS, cardiovascular diseases, and neurodegeneration.
Dewpoint Therapeutics
Dewpoint Therapeutics is a leading biotechnology company focused on translating condensate biology into novel therapies. By understanding that the dysregulation of biomolecular condensates is the root cause of complex diseases, Dewpoint is developing a new generation of medicines. They integrate AI with state-of-the-art experimental technologies to create a fully integrated discovery platform. The company has a diverse pipeline and has formed strategic partnerships with major global pharmaceutical companies like Bayer, Novo Nordisk, Evotec, Mitsubishi Tanabe Pharma Corporation, and ConcertAI. Dewpoint Therapeutics has raised significant funding, with over $287M in Series A, B, and C rounds. They have also announced development candidates such as DPTX3496 for cancers and are exploring treatments for ALS, cardiovascular diseases, and neurodegeneration.